Click here to


Are you sure ?

Yes, do it No, cancel

The Optimal Radiation Dose Rate for Pulsed Low-Dose-Rate (PLDR) Radiation Therapy Using in Vitro Clonogenic Analysis

T Dos Santos*, S Liu, L Yang, M Li, L Chen, D Cvetkovic, C Ma, Fox Chase Cancer Center, Philadelphia, PA


(Sunday, 7/12/2020)   [Eastern Time (GMT-4)]

Room: AAPM ePoster Library


To investigate the optimal radiation dose rate for pulsed low-dose-rate (PLDR) radiation therapy using in vitro clonogenic analysis.

Method and Materials:

Lung cell line A549 (Adenocarcinomic human alveolar basal epithelial cells) and human prostate cancer cells (PC3) were cultured using Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, with penicillin (50 U/ml), and streptomycin (50 µg/ml) at 37°C under 95% humidity and 5% CO2 atmosphere. All experiments used cells in the exponential growth phase by seeding ~200 cells into T-25 flasks, in triplicate, 8-10 hours before use. A clinically calibrated beam from a Varian-2100-iX machine was used to deliver a total dose of 0.25, 0.5, 1, 2 and 4 Gy to the cells. The dose rate for the CRT group was 200 cGy/min. The effective dose rates (EDR) for PLDR (8.3, 25, 60, 150 cGy/min) were determined by varying time between a train of radiation pulses, each 0.25 Gy. After irradiation, cells were incubated for 8 to 9 days, colonies were counted, and the surviving fractions of clonogenic cells were determined.


Both cell lines showed comparable responses between CRT and PLDR with different EDRs, where their survival fractions decreased with dose but were unremarkable. All PLDR groups were statistically indistinguishable among each other, and from CRT. Both cell lines were observed to be agnostic towards variation with the dose rate in radiation repair response or low-dose hyper-radiosensitivity in this study.


PLDR effect at different EDRs is comparable to that of CRT against two human cell lines. This result adds to the body of research showing PLDR’s clinical efficacy, due its equivalent tumor control and normal tissue sparing properties with decreased EDRs. PLDR may be developed into a clinically viable alternative for treating large tumor masses and/or recurrent cancers with decreased normal tissue tolerances.

Download ePoster [PDF]


Not Applicable / None Entered.


TH- Radiobiology(RBio)/Biology(Bio): RBio- general

Contact Email